We are delighted to present that Biocytogen will be attending BIO-EUROPE from November 3rd-5th in Vienna, Austria! Join us with over 5,700 attendees for 3 days full of networking, business development workshops, and a chance for innovators to showcase their findings and accomplishments in life sciences.This experience offers valuable opportunities to present innovations and foster collaborations, promoting both planned and spontaneous connections that fuel business growth and scientific progress. We hope to see you in Vienna!
What is BIO-Europe?
BIO-Europe is the premier European partnering conference for the biotech, life sciences, and pharmaceutical industries, organized in collaboration with partneringONE. Attracting over 5,700 participants from more than 60 countries annually, the event offers opportunities for high-impact one-on-one partnering meetings, allowing attendees to connect with global experts and decision-makers in the life sciences sector. The conference features business development (BD) workshops, high-level panels, company presentations, and the Startup Spotlight pitch competition, providing a platform to share innovations and explore collaboration opportunities. Attendees can also network in the exhibition hall and at social receptions, encouraging both structured and serendipitous connections that drive business growth and innovation forward.
Event Overview
Date: November 3rd - 5th, 2025
Venue: Vienna Congress and Convention Center, Messepl. 1, 1020 Wien, Austria
Event Schedule
For more information, please refer to BIO-Europe Agenda.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We can’t wait to see you at BIO-Europe!
